Gubra AS (STU:PI3) EBIT: €289.7 Mil (TTM As of Dec. 2025)


STU:PI3 Gubra AS STU:PI3
58 GF Score
Price €44.22
GF Value €381.21
Valuation Possible Value Trap
! 3 Warning Signs
View Full Analysis

What is Gubra AS EBIT?

Gubra AS STU:PI3 +0.68% 58 EBIT is €289.7 Mil as of Dec. 2025. GuruFocus rates STU:PI3 with a GF Score™ of 58/100 and a GF Value™ of €381.21 (Possible Value Trap). The stock has 3 warning signs investors should review.

Gubra AS's earnings before interest and taxes (EBIT) for the six months ended in Dec. 2025 was €-24.9 Mil. Its earnings before interest and taxes (EBIT) for the trailing twelve months (TTM) ended in Dec. 2025 was €289.7 Mil.

EBIT or Operating Income is linked to Return on Capital for both regular definition and Joel Greenblatt's definition. Gubra AS's annualized ROC % for the quarter that ended in Dec. 2025 was -65.08%. Gubra AS's annualized ROC (Joel Greenblatt) % for the quarter that ended in Dec. 2025 was -309.90%.

EBIT is also linked to Joel Greenblatt's definition of earnings yield. Gubra AS's Earnings Yield (Joel Greenblatt) % for the quarter that ended in Dec. 2025 was 48.36%.

Gubra AS  (STU:PI3) EBIT Explanation

1. EBIT or Operating Income is linked to Return on Capital for both regular definition and Joel Greenblatt's definition.

Gubra AS's annualized ROC % for the quarter that ended in Dec. 2025 is calculated as:

ROC % (Q: Dec. 2025 )
=NOPAT/Average Invested Capital
=Operating Income * ( 1 - Tax Rate % )/( (Invested Capital (Q: Jun. 2025 ) + Invested Capital (Q: Dec. 2025 ))/ count )
=-20.122 * ( 1 - 0% )/( (30.587 + 31.255)/ 2 )
=-20.122/30.921
=-65.08 %

where

Invested Capital(Q: Jun. 2025 )
=Total Assets - Accounts Payable & Accrued Expense - Excess Cash
=Total Assets - Accounts Payable & Accrued Expense - ( Cash, Cash Equivalents, Marketable Securities - max(0, Total Current Liabilities - Total Current Assets+Cash, Cash Equivalents, Marketable Securities))
=390.074 - 203.345 - ( 364.896 - max(0, 216.759 - 372.901+364.896))
=30.587

Invested Capital(Q: Dec. 2025 )
=Total Assets - Accounts Payable & Accrued Expense - Excess Cash
=Total Assets - Accounts Payable & Accrued Expense - ( Cash, Cash Equivalents, Marketable Securities - max(0, Total Current Liabilities - Total Current Assets+Cash, Cash Equivalents, Marketable Securities))
=176.717 - 1.525 - ( 144.998 - max(0, 11.394 - 155.331+144.998))
=31.255

Note: The Operating Income data used here is two times the semi-annual (Dec. 2025) data.

2. Joel Greenblatt's definition of Return on Capital:

Gubra AS's annualized ROC (Joel Greenblatt) % for the quarter that ended in Dec. 2025 is calculated as:

ROC (Joel Greenblatt) %(Q: Dec. 2025 )
=EBIT/Average of (Net fixed Assets + Net Working Capital)
=EBIT/Average of (Property, Plant and Equipment+Net Working Capital)
     Q: Jun. 2025  Q: Dec. 2025
=EBIT/( ( (Property, Plant and Equipment + Net Working Capital) + (Property, Plant and Equipment + Net Working Capital) )/ count )
=-49.71/( ( (14.409 + max(-208.817, 0)) + (17.672 + max(-0.63500000000001, 0)) )/ 2 )
=-49.71/( ( 14.409 + 17.672 )/ 2 )
=-49.71/16.0405
=-309.90 %

where Working Capital is:

Working Capital(Q: Jun. 2025 )
=(Accounts Receivable + Total Inventories + Other Current Assets) - (Accounts Payable & Accrued Expense + Defer. Rev. + Other Current Liabilities)
=(5.05 + 0 + 0.892) - (203.345 + 0 + 11.414)
=-208.817

Working Capital(Q: Dec. 2025 )
=(Accounts Receivable + Total Inventories + Other Current Assets) - (Accounts Payable & Accrued Expense + Defer. Rev. + Other Current Liabilities)
=(4.717 + 0 + 3.551) - (1.525 + 0 + 7.378)
=-0.63500000000001

When net working capital is negative, 0 is used.

Note: The EBIT data used here is two times the semi-annual (Dec. 2025) EBIT data.

3. It is also linked to Joel Greenblatt's definition of Earnings Yield:

Gubra AS's Earnings Yield (Joel Greenblatt) % for today is calculated as:

Earnings Yield (Joel Greenblatt) %=EBIT (TTM)/Enterprise Value (Q: Dec. 2025 )
=289.747/599.134
=48.36 %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Gubra AS EBIT Related Terms

Gubra AS EBIT Historical Data

* Premium members only.

The historical data trend for Gubra AS's EBIT can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Gubra AS EBIT Chart

Gubra AS Annual Data
Trend Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
EBIT
Get a 7-Day Free Trial 11.94 1.05 -5.10 -4.80 289.38

Gubra AS Semi-Annual Data
Dec19 Dec20 Dec21 Jun22 Dec22 Jun23 Dec23 Jun24 Dec24 Jun25 Dec25
EBIT Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only -2.38 -2.45 -2.35 314.60 -24.86

STU:PI3 vs VRTX, REGN, ALNY: EBIT Comparison

For the Biotechnology subindustry, Gubra AS's EV-to-EBIT, along with its competitors' market caps and EV-to-EBIT data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Gubra AS EV-to-EBIT vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Gubra AS's EV-to-EBIT distribution charts can be found below:

* The bar in red indicates where Gubra AS's EV-to-EBIT falls into.


STU:PI3
58GF Score
Gubra AS STU:PI3
EBIT is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Gubra AS EBIT Calculation

EBIT, sometimes also called Earnings Before Interest and Taxes, is a measure of a firm's profit that includes all expenses except interest and income tax expenses. It is the difference between operating revenues and operating expenses. When a firm does not have non-operating income, then Operating Income is sometimes used as a synonym for EBIT and operating profit.

EBIT for the trailing twelve months (TTM) ended in Dec. 2025 adds up the semi-annually data reported by the company within the most recent 12 months, which was €289.7 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about EBIT →
What does a EBIT of €289.7 Mil mean?
Gubra AS (STU:PI3) has a EBIT of €289.7 Mil as of Dec. 2025. Earnings before interest and taxes is the difference between operating revenue and operating expenses. View historical data on Gubra AS.
Is Gubra AS's EBIT too high?
Gubra AS's current EBIT is €289.7 Mil. Overall, Gubra AS has a GF Score™ of 58/100 and is considered Possible Value Trap, reflecting its overall financial health beyond just this single metric.
How does Gubra AS's EBIT compare to VRTX and REGN?
Gubra AS's EBIT of €289.7 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EBIT for a Biotechnology company?
A good EBIT depends on the Biotechnology industry context. However, EBIT should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EBIT mean?
A high EBIT can signal that a stock is expensive relative to its fundamentals. Earnings before interest and taxes is the difference between operating revenue and operating expenses. View historical data on Gubra AS. Gubra AS's current EBIT is €289.7 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Gubra AS stock overvalued right now?
Based on GuruFocus' analysis, Gubra AS (STU:PI3) is currently considered Possible Value Trap. The stock's GF Value™ is €381.21, compared to a current price of €44.22 — trading 88.4% below its estimated fair value. The current EBIT is €289.7 Mil. Gubra AS's overall GF Score™ is 58/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EBIT calculated?
EBIT is calculated from a company's financial statements. For Gubra AS (STU:PI3), the current EBIT is €289.7 Mil as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Gubra AS (STU:PI3) Overvalued in 2026?

Based on GuruFocus' analysis, Gubra AS stock appears to be undervalued. The current stock price of €44.22 is trading 88.4% below its estimated GF Value™ of €381.21. GuruFocus considers Gubra AS to be Possible Value Trap.

Key valuation signals for STU:PI3:

  • EBIT: €289.7 Mil
  • GF Value™: €381.21 vs. price of €44.22 (88.4% below fair value)
  • GF Score™: 58/100 with 3 warning signs

No single metric tells the full story. See the STU:PI3 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Gubra AS Business Description

Other Exchanges GUBRA:Denmark
Address Horsholm Kongevej 11B, Horsholm, DNK, 2970
Gubra AS is a specialized preclinical CRO and biotech company focused on peptide-based drug discovery within metabolic and fibrotic diseases. The company has two segments: Pre-clinical contract research (CRO), which derives maximum revenue and Biotech Segment. It derives maximum revenue from Pre-clinical contract research (CRO) segment. Geographically, the company operates in Europe, North America and Other regions.
58GF Score

Get the complete analysis for STU:PI3

EBIT is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€44.22
Price
€381.21
GF Value